DLL3 and small cell lung carcinoma: An Amgen-sponsored Phase 1 study of AMG 119 CAR T-cells targeted against DLL3 in small cell lung cancer was suspended with no patients enrolled (NCT03392064; posted November 2022, accessed on 8 January 2023).